| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Lithospermate B does not have a single defined molecular target but acts through multiple mechanisms. Its antioxidant activity is attributed to its ability to scavenge free radicals and chelate metal ions. Its anti-inflammatory effects are mediated by the inhibition of pro-inflammatory cytokines and signaling pathways, such as NF-κB. It also inhibits the formation of advanced glycation end products (AGEs), which are implicated in diabetic complications and aging.
|
|---|---|
| ln Vitro |
Magnesium violacetate B (20–60 μg/ml; 24 h) can dramatically suppress cardiomyocyte apoptosis, decrease intracellular ROS and MDA levels, raise SOD activity in cardiomyocytes, and decrease LDH activity in culture supernatant. Demise [2]. Neural stem cell (NSC) proliferation is enhanced by magnesium violacetate B (1-100 μg/ml) in a dose-dependent manner [3]. It has been observed that in vitro NSC development into neurons can be aided by magnesium lithospermate B (10 μg/ml) [3].
In vitro, Lithospermate B exhibits potent antioxidant activity, scavenging free radicals in various assay systems. It inhibits the formation of advanced glycation end products (AGEs). It also shows anti-inflammatory effects by reducing the production of pro-inflammatory cytokines in activated macrophages. These in vitro activities confirm its potential as a therapeutic agent for oxidative stress-related and inflammatory diseases. |
| ln Vivo |
By lowering reactive oxygen species, magnesium lithospermate B (2–8 mg/kg; orally, once daily for 16 days) protects the kidneys from oxidative stress in elderly rats [1]. In PD animals, magnesium violacetate B (0.5 μg/g; subcutaneous injection for 6 weeks) can enhance cognition and stimulate neurogenesis [3].
Detailed in vivo activity data for Lithospermate B are not extensively reported in the available literature. However, it has been studied in animal models of diabetic nephropathy, where it has shown renoprotective effects. Its antioxidant and anti-inflammatory properties suggest potential for in vivo efficacy in various disease models. Further studies are needed to fully characterize its in vivo profile. |
| Enzyme Assay |
Non-cell-based assays for Lithospermate B include measuring its antioxidant capacity using DPPH, ABTS, or FRAP assays. Its ability to inhibit AGE formation can be assessed by incubating the compound with a sugar (e.g., glucose or ribose) and a target protein (e.g., bovine serum albumin) and measuring the formation of fluorescent AGEs.
|
| Cell Assay |
In vitro cellular assays for Lithospermate B are performed using various cell lines, including macrophages to study anti-inflammatory effects, and renal cells to study its renoprotective effects. Cells are treated with the compound, and markers of oxidative stress, inflammation, and AGE formation are measured. Cell viability is assessed to distinguish protective effects from cytotoxicity.
|
| Animal Protocol |
Animal/Disease Models: Young (5 months old) and old (20 months old) specific pathogen-free male SD (SD (Sprague-Dawley)) rats [1]
Doses: 2, 8 mg/kg Route of Administration: po (po (oral gavage)) one time/day, continuous 16-day Experimental Results: diminished nicotinamide adenine dinucleotide phosphate oxidase (Nox4 and p22phox), phospho-p38, nuclear factor-κB p65, cyclooxygenase-2, and inducible nitric oxide synthase major subunits protein expression. demonstrated lower levels of senescence-related proteins such as p16, ADP-ribosylation factor 6, p53 and p21. In vivo animal models for Lithospermate B include models of diabetic nephropathy, where the compound is administered orally or intraperitoneally, and markers of kidney function, oxidative stress, and inflammation are assessed. Models of cardiovascular disease and neurodegenerative disorders may also be used. |
| ADME/Pharmacokinetics |
Lithospermate B has a molecular weight of 718.61 g/mol and a molecular formula of C₃₆H₃₀O₁₆. Its CAS number is 122021-74-3. The compound is a solid. Purity is typically ≥98%. It is soluble in DMSO. Storage conditions: -20°C. The compound is supplied for research use only.
|
| Toxicity/Toxicokinetics |
Detailed toxicological data for Lithospermate B are not extensively reported in the available literature. As a naturally occurring compound, it is generally considered to have a good safety profile, but thorough toxicological studies would be required for therapeutic development. The compound is intended for research use only and is not for human consumption.
|
| References |
|
| Additional Infomation |
Lithospermate B is a natural polyphenolic compound from Lithospermum erythrorhizon with antioxidant, anti-inflammatory, and neuroprotective activities. It inhibits AGE formation and has renoprotective effects. It is used in research on diabetic nephropathy, cardiovascular diseases, and neurodegenerative disorders. Its CAS number is 122021-74-3.
|
| Molecular Formula |
C36H28MGO16
|
|---|---|
| Molecular Weight |
740.9
|
| Exact Mass |
740.122
|
| CAS # |
122021-74-3
|
| PubChem CID |
6438135
|
| Appearance |
Light yellow to light brown solid powder
|
| Boiling Point |
1020.3ºC at 760mmHg
|
| Flash Point |
322.1ºC
|
| Vapour Pressure |
0mmHg at 25°C
|
| LogP |
4.21
|
| Hydrogen Bond Donor Count |
7
|
| Hydrogen Bond Acceptor Count |
16
|
| Rotatable Bond Count |
12
|
| Heavy Atom Count |
53
|
| Complexity |
1280
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1=CC(=C(C=C1CC(C(=O)[O-])OC(=O)/C=C/C2=C3C(C(OC3=C(C=C2)O)C4=CC(=C(C=C4)O)O)C(=O)OC(CC5=CC(=C(C=C5)O)O)C(=O)[O-])O)O.[Mg+2]
|
| InChi Key |
ANUBYMNVOPVATP-OAZHBLANSA-L
|
| InChi Code |
InChI=1S/C36H30O16.Mg/c37-20-6-1-16(11-24(20)41)13-27(34(45)46)50-29(44)10-5-18-3-9-23(40)33-30(18)31(32(52-33)19-4-8-22(39)26(43)15-19)36(49)51-28(35(47)48)14-17-2-7-21(38)25(42)12-17;/h1-12,15,27-28,31-32,37-43H,13-14H2,(H,45,46)(H,47,48);/q;+2/p-2/b10-5+;
|
| Chemical Name |
magnesium;2-[(E)-3-[3-[1-carboxylato-2-(3,4-dihydroxyphenyl)ethoxy]carbonyl-2-(3,4-dihydroxyphenyl)-7-hydroxy-2,3-dihydro-1-benzofuran-4-yl]prop-2-enoyl]oxy-3-(3,4-dihydroxyphenyl)propanoate
|
| Synonyms |
Magnesium tanshinoate B; Magnesium lithospermate B; Lithospermate B
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~50 mg/mL (~67.49 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (3.37 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (3.37 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.3497 mL | 6.7485 mL | 13.4971 mL | |
| 5 mM | 0.2699 mL | 1.3497 mL | 2.6994 mL | |
| 10 mM | 0.1350 mL | 0.6749 mL | 1.3497 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
